IOVANCE BIOTHERAPEUTICS INC

For the period ended Dec 31, 2023. Filed Feb 28, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 28, 2024

IOVA$8.08-1.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 8. Consolidated Statements of Cash Flows

Consolidated Statements of Cash Flows

(In thousands)



· · · Years Ended December 31,
· · 2023 · 2022 · 2021
Cash Flows from Operating Activities · · · ·
Net loss	$(444,037)	$(395,893)	$(342,252)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	62,625	84,022	69,765
Unrealized exchange gains	70	—	—
Amortization of intangible assets	9,849	—	—
Amortization of right of use asset	11,710	11,825	10,869
Depreciation and amortization of property and equipment	11,568	9,310	3,111
Deferred tax benefit	(3,479)	—	—
Accretion of discounts and premiums on investments	(3,605)	474	6,013
Loss on write-off of fixed assets	—	397	—
Changes in assets and liabilities:
Prepaid expenses, other assets and long-term assets	(10,062)	(2,130)	2,775
Trade accounts receivable	(149)	—	—
Inventory	(10,118)	—	—
Operating lease liabilities	(10,794)	(1,942)	(5,882)
Accounts payable	4,828	5,883	6,976
Accrued expenses and other liabilities	19,774	(4,703)	20,684
Net cash used in operating activities	(361,820)	(292,757)	(227,941)

Cash Flows from Investing Activities
Maturities of investments	285,583	522,696	762,914
Purchase of investments	(205,902)	(245,816)	(725,208)
Cash paid for acquisition, net of cash acquired	(212,633)	—	—
Purchase of property and equipment	(22,290)	(20,425)	(37,574)
Net cash provided by / (used in) investing activities	(155,242)	256,455	132

Cash Flows from Financing Activities
Tax payments related to shares withheld for vested restricted stock units	(2,795)	(2,649)	—
Proceeds from the issuance of common stock under employee stock purchase plan	2,410	1,655	1,586
Proceeds from the issuance of common stock upon exercise of options	63	1,642	33,526
Proceeds from the issuance of common stock, net	463,281	189,502	203,156
Proceeds from the issuance of debt	—	—	1,000
Net cash provided by financing activities	462,959	190,150	239,268
Effect of exchange rate changes	(2,740)
Net increase in cash, cash equivalents and restricted cash	(56,843)	153,848	11,459
Cash, Cash Equivalents and Restricted Cash Beginning of Period	238,161	84,313	72,854
Cash, Cash Equivalents and Restricted Cash End of Period	$181,318	$238,161	$84,313

Supplemental disclosure of non-cash investing and financing activities:
Fair value of net assets acquired	$222,637	—	—
Net unrealized gain (loss) on investments	940	$(301)	(620)
Acquisition of property and equipment included in accounts payable and accrued expenses	4,062	5,985	12,410
Conversion of convertible preferred stock to common stock	—	—	1
Lease liabilities arising from obtaining right-of-use asset from new leases	177	553	17,275
Lease liabilities arising from obtaining right-of-use asset from lease modifications	1,033	15,304	7,800

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.